Disc Medicine (IRON) Competitors

Disc Medicine (NASDAQ:IRON) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, community ranking, institutional ownership, earnings, profitability and risk.

Does the MarketBeat Community believe in IRON or GRFS?

Grifols received 293 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 85.51% of users gave Disc Medicine an outperform vote while only 56.23% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
Disc Medicine	Outperform Votes 59 85.51%	Underperform Votes 10 14.49%
Grifols	Outperform Votes 352 56.23%	Underperform Votes 274 43.77%

Does the media prefer IRON or GRFS?

In the previous week, Disc Medicine had 5 more articles in the media than Grifols. MarketBeat recorded 9 mentions for Disc Medicine and 4 mentions for Grifols. Grifols' average media sentiment score of 1.07 beat Disc Medicine's score of 1.02 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable earnings and valuation, IRON or GRFS?

Grifols has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$76.43M	-$3.92	-13.54
Grifols	$7.21B	0.86	$64.20M	$1.17	7.71

Do analysts prefer IRON or GRFS?

Disc Medicine presently has a consensus price target of $98.80, indicating a potential upside of 86.17%. Given Disc Medicine's higher probable upside, equities research analysts clearly believe Disc Medicine is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Which has more volatility and risk, IRON or GRFS?

Disc Medicine has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Is IRON or GRFS more profitable?

Grifols' return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-25.24%	-23.96%
Grifols	N/A	N/A	N/A

Do institutionals & insiders believe in IRON or GRFS?

83.7% of Disc Medicine shares are held by institutional investors. 4.2% of Disc Medicine shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Grifols beats Disc Medicine on 9 of the 16 factors compared between the two stocks.